Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

A large study published in Nature Medicine reviewed the effects of GLP-1 drugs like Ozempic and Mounjaro on 175 different ...

Mounjaro can cause mild to moderate side effects, such as nausea, vomiting, constipation, and indigestion. According to Eli ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a serious complication.

If you’re in a calorie deficit – either from dieting or while taking a weight loss drug – these exercises help direct your ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Mounjaro and Zepbound are by far Lilly's fastest-growing businesses, and the company's momentum in the GLP-1 realm seems to be the only thing Wall Street analysts are talking about these days.

FreshSplash/Getty Images Researchers report that GLP-1 drugs prescribed for weight loss, like Ozempic and Mounjaro, may improve cognition and lower dementia and cardiovascular disease risk.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, ...